Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

      © 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

carvedilol top

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Carvedilol Manufacturers in India Suppliers Carvedilol Dossage Exporters Distributors Carvedilol api active pharmaceuticals ingredients Carvedilol manufacturers Side Effects bulk drugs raw material Dossage Carvedilol companies Side Effects Dossage Importers Carvedilol Dossage Carvedilol Exporters Carvedilol exporters Dossage FDA Dossage Carvedilol Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Carvedilol manufacturing pharmaceutical drugs pharmaceutical intermediates Carvedilol pharmaceutical chemicals pharmaceutical raw materials Carvedilol active pharmaceutical ingredients Carvedilol committee active pharmaceutical ingredients manufacturer Carvedilol Active Pharmaceutical Ingredients manufacturer Carvedilol exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Carvedilol, Carvedilol manufacturer India, Carvedilol product, Carvedilol products, Api preparation, Certificate of Analysis API manufacturer product, Carvedilol anti ulcer product, Certificate of Origin COA Carvedilol COS Carvedilol, pharmaceutical generic, pharmaceutical drug, medical, Carvedilol pharma healthcare, pharma patents, contract MSDS manufacturing Trader Carvedilol pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Carvedilol expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Carvedilol DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Carvedilol ingredients, api, HIV Carvedilol, tablets, capsules, syrup & protein Carvedilol powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Carvedilol gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Carvedilol WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

carvedilol  img.







HOME >> API >> API List1 >> Carvedilol >> Dosage

carvedilol CAS No [72956-09-3]

Carvedilol CAS No [72956-09-3]

The starting dosage of carvedilol is 3.125 mg orally twice daily for two weeks. This dosage is the same regardless of the patient's age or weight. Because food slows the rate (but not the extent) of absorption, carvedilol should be taken with food to reduce the incidence of orthostatic hypotension. Patients should be observed in the physician's office for adverse reactions, especially dizziness, lightheadedness and hypotension, for one hour after the first dose and again after each dosage increase. Blood pressure should be measured with the patient standing. Patients should be instructed to weigh themselves every day and to contact their physician immediately if they experience a weight gain of 0.91 to 1.36 kg (2 to 3 lb) above their usual "dry" weight. If, after two weeks, the initial dosage of carvedilol has been well-tolerated, it should be doubled. The dosage should be doubled every two weeks to the maximum dosage or the highest tolerated dosage. The maximum recommended dosage for carvedilol is 25 mg twice daily in patients weighing less than 85 kg (187 lb) and 50 mg twice daily in patients weighing 85 kg (187 lb) or moreRecommendations for the administration and titration of carvedilol are summarized in Tables 3 and 4.It may also be necessary, based on clinical signs and symptoms, to adjust the dosages of the patient's other heart failure medications when carvedilol is introduced. When patients have signs and symptoms of excessive vasodilation, such as dizziness, lightheadedness or orthostatic hypotension, consideration should be given to decreasing diuretic, vasodilator or ACE inhibitor dosages. If these signs and symptoms persist, the dosage of carvedilol should be decreased. In patients with signs and symptoms of worsening heart failure, such as edema, weight gain or dyspnea, the dosage of diuretic therapy should be increased. If evidence of worsening heart failure persists, the dosage of carvedilol should be decreased. In patients with bradycardia or first-degree atrioventricular block, carvedilol should be titrated to maintain a heart rate greater than 55 beats per minute. Finally, patients should be advised not to stop taking carvedilol abruptly or without a physician's advice. When carvedilol therapy must be discontinued, the drug should be tapered slowly over seven to 14 days

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo


Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium



Clopidogrel Bisulfate



Atomoxetine Hcl



Desmopressin Monoacetate


Divalproex Sodium


Dobutamine Hcl

Bupropion Hcl



Dothiepin Hcl






Escitalopram HBr





Cefuroxime Axetil



Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.